Janux Therapeutics, Inc.

Trading arrangements

During the three months ended September 30, 2026, no director or officer adopted orterminated any Rule 10b5-1 trading arrangement or any non-Rule 10b5-1 trading arrangement (as such terms are defined pursuant to Item 408(a) of Regulation S-K).

In addition, our officers (as defined in Rule 16a-1(f) under the Exchange Act) previously entered into sell-to-cover arrangements adopted pursuant to Rule 10b5-1 authorizing the pre-arranged sale of shares to satisfy our tax withholding obligations arising exclusively from the vesting of restricted stock units. The number of shares to be sold to satisfy our tax withholding obligations under these arrangements is dependent on future events which cannot be known at this time, including the future trading price of our shares. The expiration date relating to these arrangements is dependent on future events which cannot be known at this time, including the final vesting date of the applicable restricted stock units and the officer’s termination of service.

Return of Maria Dobek as Principal Accounting Officer

Effective as of November 4, 2026, following her return from a leave of absence, Maria Dobek resumed serving as our Principal Accounting Officer. In connection with Ms. Dobek’s resumption of her role as Principal Accounting Officer, Janeen Doyle ceased serving as Interim Principal Accounting Officer on the same date.